[1]. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
Arthritis & rheumatology (Hoboken, N.J.) (2024年) [査読] 有
[DOI] [2]. 外的要因と抜け毛 新型コロナウイルス感染症も含めて
皮膚と美容 (公社)日本毛髪科学協会 [巻]55 [号]4 [頁]132 -132-138 (2023年) [査読] 有
[3]. Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.
Dermatology and therapy [巻]13 [号]11 [頁]2621 -2634 (2023年) [査読] 有
[DOI] [4]. Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY [巻]89 [号]3 [頁]AB42 -AB42 (2023年) [査読] 有
[5]. 日本皮膚科学会マニュアル 安全使用マニュアル リトレシチニブトシル酸塩(販売名:リットフーロカプセル50mg) 円形脱毛症
日本皮膚科学会 [巻]133 [号]10 [頁]2313 -2323 (2023年) [査読] 有
[DOI]